Rania Alaaeldin1, Gamal El-Din A Abuo-Rahma2, Qing-Li Zhao3, Moustafa Fathy4,5. 1. Department of Biochemistry, Faculty of Pharmacy, Deraya University, Minia, Egypt. 2. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Deraya University, Minia, Egypt. 3. Department of Radiology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan; zhao@med.u-toyama.ac.jp. 4. Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia, Egypt. 5. Department of Regenerative Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Abstract
BACKGROUND/AIM: This study aimed to investigate the effect of the new ciprofloxacin chalcone [7-(4-(N-substituted carbamoyl methyl) piperazin-1 yl)] on the proliferation, migration, and metastasis of MCF-7 and MDA-MB-231 breast cancer cell lines. MATERIALS AND METHODS: Cell viability, colony formation and cell migration abilities were analysed. Cell cycle distribution and apoptosis were examined by flow cytometry. The molecular mechanism underlying chalcone's activity was investigated using qRT-PCR and western blotting. RESULTS: This new ciprofloxacin chalcone significantly inhibited proliferation, colony formation, and cell migration abilities of both cancer cell lines. Furthermore, it initiated apoptosis and caused cell cycle arrest at G2/M and S phase in MCF-7 and MDA-MB-231 cell lines, respectively. In addition, it up-regulated the expression of pro-apoptotic factors, p53, PUMA and NOXA, and down-regulated the expression of anti-apoptotic factors, MDM2 and MDM4. At the same time, it inhibited epithelial-mesenchymal transition by increasing the expression of E-cadherin and decreasing the expression of TGF-β1, SNAI1, TWIST1, MMP2, and MMP9. CONCLUSION: This new ciprofloxacin chalcone exhibited promising apoptotic and anti-metastatic activities against MCF-7 and MDA-MB-231 breast cancer cell lines, and, therefore, is an attractive molecule for drug development in the treatment of breast cancer.
BACKGROUND/AIM: This study aimed to investigate the effect of the new ciprofloxacinchalcone [7-(4-(N-substituted carbamoyl methyl) piperazin-1 yl)] on the proliferation, migration, and metastasis of MCF-7 and MDA-MB-231breast cancer cell lines. MATERIALS AND METHODS: Cell viability, colony formation and cell migration abilities were analysed. Cell cycle distribution and apoptosis were examined by flow cytometry. The molecular mechanism underlying chalcone's activity was investigated using qRT-PCR and western blotting. RESULTS: This new ciprofloxacinchalcone significantly inhibited proliferation, colony formation, and cell migration abilities of both cancer cell lines. Furthermore, it initiated apoptosis and caused cell cycle arrest at G2/M and S phase in MCF-7 and MDA-MB-231 cell lines, respectively. In addition, it up-regulated the expression of pro-apoptotic factors, p53, PUMA and NOXA, and down-regulated the expression of anti-apoptotic factors, MDM2 and MDM4. At the same time, it inhibited epithelial-mesenchymal transition by increasing the expression of E-cadherin and decreasing the expression of TGF-β1, SNAI1, TWIST1, MMP2, and MMP9. CONCLUSION: This new ciprofloxacinchalcone exhibited promising apoptotic and anti-metastatic activities against MCF-7 and MDA-MB-231breast cancer cell lines, and, therefore, is an attractive molecule for drug development in the treatment of breast cancer.
Authors: Michael A Fawzy; Sherif A Maher; Mahmoud A El-Rehany; Nermeen N Welson; Nisreen K A Albezrah; Gaber El-Saber Batiha; Moustafa Fathy Journal: Molecules Date: 2022-02-18 Impact factor: 4.411
Authors: Marwa A Eisa; Moustafa Fathy; Gamal El-Din A A Abuo-Rahma; Mohamed Abdel-Aziz; Maiiada Hassan Nazmy Journal: Asian Pac J Cancer Prev Date: 2021-10-01
Authors: Rania Alaaeldin; Iman A M Abdel-Rahman; Heba Ali Hassan; Nancy Youssef; Ahmed E Allam; Sayed F Abdelwahab; Qing-Li Zhao; Moustafa Fathy Journal: Molecules Date: 2021-12-16 Impact factor: 4.411
Authors: Soad A Mohamed; Mohamed A Abdelgawad; Rania Alaaeldin; Zeinab Fathalla; Hossam Moharram; Raafat M A Abdallah; Islam M Abdel-Rahman; Mohamed Abdel-Aziz; Gamal El-Din A Abuo-Rahma; Mohammed M Ghoneim; Alaa M Hayallah; Mahmoud Elrehany; Hamdy Abdelkader Journal: Pharmaceuticals (Basel) Date: 2021-12-29